Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

• Status: Completed
• Trial end date: 2017-03-27
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted to investigate whether the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 14 days in the treatment of H pylori infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zahra Vahdat Shariatpanahi
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Esomeprazole; Lansoprazole; Tinidazole

Criteria

Inclusion Criteria:

• The patients who proved H. pylori infection following three methods

• Positive rapid urease test

• Histologic evidence of H. pylori by modified Giemsa staining

• Positive stool Antigen Test

Exclusion Criteria:

• Patients who received eradication therapy for H. pylori infection, previously

• H. pylori eradication failure because of poor compliance

• The administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks

• Advanced gastric cancer or other malignancy

• Abnormal liver function or liver cirrhosis

• Abnormal renal function or chronic kidney disease

• Other severe concurrent diseases

• Previous allergic reactions to the study drugs

• Pregnant or lactating women